Category: 39919-70-5

On November 9, 2006, Kelly, Michael G.; Kincaid, John; Kaub, Carl J. published a patent.Related Products of 39919-70-5 The title of the patent was Preparation of fused heterocyclic compounds for preventing and treating various diseases. And the patent contained the following:

The title compounds I [A, B = (un)substituted CH2, CO or CS; Y = (un)substituted CH2; W = CR4, N; Z = O, NR2; L = (hetero)alkylene; R1 = carbocyclyl or heterocyclyl; R2 = H, alkyl, cycloalkyl; R3 = carbocyclyl or heterocyclyl; R4 = H, alkyl, acyl, etc.; R5 = R4, Z’-L’-R4 (wherein Z’ = a bond, O, S, etc.; L’ = alkylene)], useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others, were prepared and formulated. E.g., a multi-step synthesis of II, starting from Et 1-benzyl-4-oxopiperidine-3-carboxylate hydrochloride, was given. The exemplified compounds I were tested in calcium uptake assay (P2X2 and P2X3) and % inhibition data were given for representative compounds I. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Related Products of 39919-70-5

The Article related to fused heterocycle pyridopyrimidinamine preparation purinoceptor antagonist analgesic antiinflammatory anxiolytic, cognition enhancer pyridopyrimidinamine preparation purinoceptor antagonist, antidepressant pyridopyrimidinamine preparation purinoceptor antagonist and other aspects.Related Products of 39919-70-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On July 29, 2021, Rai, Roopa; Booth, Robert; Green, Michael J. published a patent.Name: 6-(tert-Butyl)pyridin-3-amine The title of the patent was Preparation of substituted (aza)benzimidazole-, indole-, quinolinecarboxamides and analogs as PGDH inhibitors. And the patent contained the following:

The title compounds I [X = OCH2, C(O)NH, NHC(O), etc.; each Y = (independently) N and substituted CH; each R1 = (independently) halo, (halo)alkyl, cycloalkyl, etc.; R2 = H and R3 = CF3; or R2 and R3 are taken together to form oxo or thio; each R4 = (independently) halo, (halo)alkyl, cycloalkyl, etc.; each R5 = (independently) halo, (halo)alkyl, cycloalkyl, etc.; n = 0-5; m = 0-4; and p = 0-10; with the proviso] or pharmaceutically acceptable salts thereof that can inhibit 15-hydroxyprostaglandin dehydrogenase, were prepared E.g., a multi-step synthesis of II, starting from 4-fluoro-3-nitrobenzoic acid, was described. Exemplified compounds I were evaluated in the hPGDH inhibitor screening biochem. assay (data given for representative compounds I). Compounds I may be administered to subjects that may benefit from modulation of prostaglandin levels. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Name: 6-(tert-Butyl)pyridin-3-amine

The Article related to benzimidazole azabenzimidazole indole quinoline carboxamide preparation pgdh inhibitor, prostaglandin level modulator benzimidazole azabenzimidazole indole quinoline carboxamide preparation, hydroxyprostaglandin dehydrogenase inhibitor benzimidazole azabenzimidazole indole quinoline carboxamide preparation and other aspects.Name: 6-(tert-Butyl)pyridin-3-amine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On July 16, 2015, Stoessel, Philipp; Koenen, Nils published a patent.Recommanded Product: 6-(tert-Butyl)pyridin-3-amine The title of the patent was Cyclometalated arylpyridine and arylbenzimidazolylidene metal complexes as electroluminescent materials for organic light-emitting devices. And the patent contained the following:

Cyclometalated iridium complexes [(Q1-Q2)3Ir] (1), [(Q1-Q2)2(Q3-Q4)Ir] (2) and [(Q1-Q2)2IrL] (3; for 1-3: Q1, Q3 = substituted pyridinyl-κN, quinolinyl-κN, isoquinolinyl-κN, benzimidazolylidene-κC2; Q2, Q4 = substituted aryl-κC2; L = acetylacetonato, dipivaloylmethanato), useful as triplet-emitting dopants for light-emitting layers of organic electroluminescent devices (OLEDs), featuring better solubility in organic solvents and enhanced stability, were prepared by conventional cyclometalation, ligand substitution and derivatization reactions and tested for performance and electrooptical characteristics by manufacturing test OLEDs according to standard protocols. The homoleptic complexes 1 were prepared by cyclometalation of the corresponding ligands Q1-Q2H with [Ir(acac)3], typically as fac-isomers. The heteroleptic tris-cyclometalated complexes 2 were prepared via cationic intermediates [(Q1-Q2)2Ir(HOMe)2][OTf] (4), which were results of halogen abstraction and methanolysis of iridium dimers [(Q1-Q2)4Ir2(μ-Cl)2] (5), by cyclometalation of the ligands Q3-Q4H with 4. The complexes of the type 3 were prepared by complexation of dimers 5 or methanol complexes 4 with the β-diketones HL. The ligands in the some of the complexes 1 or 2 were modified by bromination, borylation and coupling reaction sequence; the bromides [(Q1-Q2-Br)3Ir] (6) were arylated via Suzuki coupling with arylboronates or converted into aromatic amines [(Q1-Q2-NR2)3Ir] (R = aryl, or NR2 = substituted 9-carbazolyl) by Buchwald amination reaction with amines HNR2 or carbazoles. The bromides 6 were also used as comonomers in Suzuki polymerization of arene and carbazole dibromides with arylenediboronates, giving electroluminescent polyarylene-polycarbazoles containing up to 10% of [(Q1-Q2)3Ir] structural fragments. In an example, reaction of 10 mmol of Na[(acac)2IrCl2] with 40 mmol of the proligand, 2-(1,2,3,4-tetrahydro-1,4-ethano-6-naphthyl)pyridine (H-LB1) in the presence of 3-10 g of propylene glycol as solvent at reflux for 100 h gave the reaction mixture, which was diluted with 50 mL of EtOH and 50 mL of 2 N HCl, the product was filtered off, and purified by EtOAc extraction to give the invented complex [(LB1)3Ir] (1a) with 49% yield. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Recommanded Product: 6-(tert-Butyl)pyridin-3-amine

The Article related to iridium cyclometalated arylpyridine arylquinoline arylisoquinoline arylbenzimidazole complex preparation electroluminescence, electroluminescent material iridium cyclometalated complex preparation luminescence oled manufacturing, bromination borylation suzuki buchwald coupling derivatization iridium cyclometalated complex and other aspects.Recommanded Product: 6-(tert-Butyl)pyridin-3-amine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On January 8, 2015, Stoessel, Philipp; Joosten, Dominik; Koenen, Nils published a patent.Reference of 6-(tert-Butyl)pyridin-3-amine The title of the patent was Polycyclic nitrogen heterocyclic compounds as semiconducting materials for components of organic electronic devices. And the patent contained the following:

Polycyclic nitrogen heterocycles I (1, X = methyne, N; E = bivalent group, forming 5- or 6-membered condensed ring; Y = O, S, 1,2-ethenediyl, imino, borylene, silylene CO, alkenylidene, SO, SO2, 1,2-ethanediyl, phosphinidene, phosphinylidene; R = H, D, halo, amino, CN, NO2, OH, CO2H, carbamoyl, silyl, boryl, acyl, phosphinyl, sulfinyl, sulfonyl, sulfo, C1-20 alkyl, alkoxy, alkylthio, alkenyl, alkynyl; R1 = R or R1-R1 = bond) and their cyclometalated platinum and iridium complexes [M(L)n(L1)m] (2, M = Ir, Pd, Pt, Os, Re; L1 = auxiliary ligand), useful as organic semiconducting materials for manufacturing of charge-transporting and charge-injecting layers in organic semiconductor devices, preferably, in organic light-emitting devices (OLEDs) and featuring glass transition temperature at least 110°, were prepared by heterocyclization of aromatic aldehydes with aromatic amines and alkenes with optional subsequent cyclometalation and complexation with protonated ligands HpL1. In an example, Povarov reaction of 500 mmol of aniline with 550 mmol of benzaldehyde and 1 mol of norbornene in 1300 mL of CH2Cl2 catalyzed with 100 mmol of BF3·OEt2 for 40 h at reflux with subsequent oxidation by 5 mol of MnO2 for 16 h at reflux in 1000 mL of 1,2-dichlorobenzene under water separation gave the invented compound (1a, shown as I, E = CH:CHCH:CH, X = CH, Y = CH2, R = R1 = H) with 56% yield. The present invention relates to compounds having polycyclic structural units and to electronic devices, in particular organic electroluminescent devices, containing said compounds The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Reference of 6-(tert-Butyl)pyridin-3-amine

The Article related to nitrogen heterocyclic compound preparation povarov cyclization cycloalkene aldehyde amine, heterocyclic polycyclic aromatic nitrogen preparation component organic electronic device, organic semiconductor nitrogen heterocycle host hole electron transporter, metallacyclic complex iridium platinum nitrogen heterocycle preparation electroluminescence and other aspects.Reference of 6-(tert-Butyl)pyridin-3-amine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On July 21, 2005, Kelly, Michael G.; Janagani, Satyanarayana; Wu, Guoxian; Kincaid, John; Lonergan, David; Fang, Yunfeng; Wei, Zhi-Liang published a patent.Related Products of 39919-70-5 The title of the patent was Preparation of bicycloheteroarylamines like 2,6-naphthyridinamines and pyrido[3,4-d]pyrimidinamine as ion channel ligands and uses thereof. And the patent contained the following:

Amine compounds (shown as I; or a pharmaceutically acceptable salt, solvate or prodrug thereof; and stereoisomers and tautomers thereof; variables defined below; e.g. 7-(3-chloropyridin-2-yl)-N-[4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-amine (shown as II)) that are VR1 (VR = vanilloid receptor) antagonists are disclosed. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of nonlimiting example, pain, inflammation, traumatic injury, and others. Compounds I are considered to be particularly beneficial as VR1 antagonists as certain compounds exhibit improved aqueous solubility and metabolic stability. For I: A and B = CH2, CR2’R2′, CO, CS and NR2′; Y = CH2, CR2’R2′ and NR2′; W and Z = CR4 and N, provided that W and Z both can not be N; R1 = (un)substituted aliphatic, alkyl, heteroalkyl, acyl, aryl, heteroaryl, aralkyl, heteroalkyl; each of R2 and R2′ = H, or (un)substituted C1-C6 alkyl, C1-C6 cycloalkyl, aryl and aralkyl; R3 = (un)substituted C1-C6 alkyl, aryl, heteroaryl, heteroalkyl, cycloalkyl, cycloheteroalkyl, cycloalkenyl, cycloheteroalkenyl, bicycloalkyl, bicycloheteroalkyl, bicycloalkenyl, bicycloheteroalkenyl, bicycloaryl, and bicycloheteroaryl ring. R4 = H, or (un)substituted alkyl, (un)substituted acyl, (un)substituted acylamino, (un)substituted alkylamino, (un)substituted alkylthio, (un)substituted alkoxy, (un)substituted alkoxycarbonyl, (un)substituted alkylarylamino, (un)substituted arylalkyloxy, amino, (un)substituted aryl, arylalkyl, (un)substituted sulfoxide, (un)substituted sulfone, (un)substituted mercapto, (un)substituted aminosulfonyl, (un)substituted arylsulfonyl, sulfuric acid, sulfuric acid ester, (un)substituted dihydroxyphosphoryl, (un)substituted aminodihydroxyphosphoryl, azido, carboxy, (un)substituted carbamoyl, carboxy, cyano, (un)substituted cycloalkyl, (un)substituted cycloheteroalkyl, (un)substituted dialkylamino, halo, heteroaryloxy, (un)substituted heteroaryl, (un)substituted heteroalkyl, hydroxy, nitro, and thio. Although the methods of preparation are not claimed, 62 example preparations are included. For example, II was prepared in 5 steps (90, 38, 91, 87, 26 % yields) starting from 1-benzyl-3-(ethoxycarbonyl)-4-piperidone hydrochloride, formamidine acetate and NaOMe/MeOH and involving intermediates 7-benzyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-one, 7-benzyl-4-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine, 7-benzyl-N-[4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-amine, and N-[4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-amine. VR1 antagonist activity for 62 examples of I, capsaicin-induced VR1 current inhibition activity for 16 examples of I, reversal of thermal hyperalgesia in rats by II, pharmacokinetic profiles for 5 examples of I and plasma protein binding ability by II are reported. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Related Products of 39919-70-5

The Article related to naphthyridinamine pyridopyrimidinamine preparation vanilloid receptor antagonist, ion channel ligand naphthyridinamine pyridopyrimidinamine preparation, pain inflammation traumatic injury drug naphthyridinamine pyridopyrimidinamine preparation and other aspects.Related Products of 39919-70-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On April 21, 2022, Rai, Roopa; Booth, Robert published a patent.COA of Formula: C9H14N2 The title of the patent was Preparation of 1H-pyrrolo[2,3-b]pyridine derivatives as PGDH inhibitors and inhalation formulations thereof. And the patent contained the following:

Disclosed are compounds that inhibit 15-hydroxy-prostaglandin dehydrogenase (PGDH) thus modulating prostaglandin levels which may be useful for the treatment of respiratory disorders such as COPD and idiopathic pulmonary fibrosis. Compounds of formula I [wherein R1 = (un)substituted C6-10aryl and 5- to 10-membered heteroaryl; R2 = H and R3 = CF3; R2 and R3 together = O; each R4 and R5 independently = halo, OH and derivatives, NH2 and derivatives, etc.; m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; n = 1, 2, 3, or 4; p = 0, 1, 2, or 3] or pharmaceutically acceptable salts thereof, are claimed and exemplified. Example compound II was prepared from a multistep procedure (preparation given). Exemplified I were evaluated for PGDH inhibitory activity from which II demonstrated an IC50 of < 0.1μM. In some embodiments, the compounds disclosed herein are formulated for delivery via inhalation. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).COA of Formula: C9H14N2

The Article related to pyrrolopyridine carboxamide derivative preparation inhalant formulation, hydroxyprostaglandin dehydrogenase inhibitor preparation pulmonary fibrosis copd, benzimidazole azabenzimidazole indole benzoxazine carboxamide preparation prostaglandin inhibitor and other aspects.COA of Formula: C9H14N2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On November 9, 2006, Kelly, Michael G.; Kincaid, John; Kaub, Carl J. published a patent.Related Products of 39919-70-5 The title of the patent was Preparation of fused heterocyclic compounds for preventing and treating various diseases. And the patent contained the following:

The title compounds I [A, B = (un)substituted CH2, CO or CS; Y = (un)substituted CH2; W = CR4, N; Z = O, NR2; L = (hetero)alkylene; R1 = carbocyclyl or heterocyclyl; R2 = H, alkyl, cycloalkyl; R3 = carbocyclyl or heterocyclyl; R4 = H, alkyl, acyl, etc.; R5 = R4, Z’-L’-R4 (wherein Z’ = a bond, O, S, etc.; L’ = alkylene)], useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others, were prepared and formulated. E.g., a multi-step synthesis of II, starting from Et 1-benzyl-4-oxopiperidine-3-carboxylate hydrochloride, was given. The exemplified compounds I were tested in calcium uptake assay (P2X2 and P2X3) and % inhibition data were given for representative compounds I. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Related Products of 39919-70-5

The Article related to fused heterocycle pyridopyrimidinamine preparation purinoceptor antagonist analgesic antiinflammatory anxiolytic, cognition enhancer pyridopyrimidinamine preparation purinoceptor antagonist, antidepressant pyridopyrimidinamine preparation purinoceptor antagonist and other aspects.Related Products of 39919-70-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On January 8, 2015, Stoessel, Philipp; Joosten, Dominik; Koenen, Nils published a patent.Reference of 6-(tert-Butyl)pyridin-3-amine The title of the patent was Polycyclic nitrogen heterocyclic compounds as semiconducting materials for components of organic electronic devices. And the patent contained the following:

Polycyclic nitrogen heterocycles I (1, X = methyne, N; E = bivalent group, forming 5- or 6-membered condensed ring; Y = O, S, 1,2-ethenediyl, imino, borylene, silylene CO, alkenylidene, SO, SO2, 1,2-ethanediyl, phosphinidene, phosphinylidene; R = H, D, halo, amino, CN, NO2, OH, CO2H, carbamoyl, silyl, boryl, acyl, phosphinyl, sulfinyl, sulfonyl, sulfo, C1-20 alkyl, alkoxy, alkylthio, alkenyl, alkynyl; R1 = R or R1-R1 = bond) and their cyclometalated platinum and iridium complexes [M(L)n(L1)m] (2, M = Ir, Pd, Pt, Os, Re; L1 = auxiliary ligand), useful as organic semiconducting materials for manufacturing of charge-transporting and charge-injecting layers in organic semiconductor devices, preferably, in organic light-emitting devices (OLEDs) and featuring glass transition temperature at least 110°, were prepared by heterocyclization of aromatic aldehydes with aromatic amines and alkenes with optional subsequent cyclometalation and complexation with protonated ligands HpL1. In an example, Povarov reaction of 500 mmol of aniline with 550 mmol of benzaldehyde and 1 mol of norbornene in 1300 mL of CH2Cl2 catalyzed with 100 mmol of BF3·OEt2 for 40 h at reflux with subsequent oxidation by 5 mol of MnO2 for 16 h at reflux in 1000 mL of 1,2-dichlorobenzene under water separation gave the invented compound (1a, shown as I, E = CH:CHCH:CH, X = CH, Y = CH2, R = R1 = H) with 56% yield. The present invention relates to compounds having polycyclic structural units and to electronic devices, in particular organic electroluminescent devices, containing said compounds The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Reference of 6-(tert-Butyl)pyridin-3-amine

The Article related to nitrogen heterocyclic compound preparation povarov cyclization cycloalkene aldehyde amine, heterocyclic polycyclic aromatic nitrogen preparation component organic electronic device, organic semiconductor nitrogen heterocycle host hole electron transporter, metallacyclic complex iridium platinum nitrogen heterocycle preparation electroluminescence and other aspects.Reference of 6-(tert-Butyl)pyridin-3-amine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On July 29, 2021, Rai, Roopa; Booth, Robert; Green, Michael J. published a patent.Name: 6-(tert-Butyl)pyridin-3-amine The title of the patent was Preparation of substituted (aza)benzimidazole-, indole-, quinolinecarboxamides and analogs as PGDH inhibitors. And the patent contained the following:

The title compounds I [X = OCH2, C(O)NH, NHC(O), etc.; each Y = (independently) N and substituted CH; each R1 = (independently) halo, (halo)alkyl, cycloalkyl, etc.; R2 = H and R3 = CF3; or R2 and R3 are taken together to form oxo or thio; each R4 = (independently) halo, (halo)alkyl, cycloalkyl, etc.; each R5 = (independently) halo, (halo)alkyl, cycloalkyl, etc.; n = 0-5; m = 0-4; and p = 0-10; with the proviso] or pharmaceutically acceptable salts thereof that can inhibit 15-hydroxyprostaglandin dehydrogenase, were prepared E.g., a multi-step synthesis of II, starting from 4-fluoro-3-nitrobenzoic acid, was described. Exemplified compounds I were evaluated in the hPGDH inhibitor screening biochem. assay (data given for representative compounds I). Compounds I may be administered to subjects that may benefit from modulation of prostaglandin levels. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Name: 6-(tert-Butyl)pyridin-3-amine

The Article related to benzimidazole azabenzimidazole indole quinoline carboxamide preparation pgdh inhibitor, prostaglandin level modulator benzimidazole azabenzimidazole indole quinoline carboxamide preparation, hydroxyprostaglandin dehydrogenase inhibitor benzimidazole azabenzimidazole indole quinoline carboxamide preparation and other aspects.Name: 6-(tert-Butyl)pyridin-3-amine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On July 16, 2015, Stoessel, Philipp; Koenen, Nils published a patent.Recommanded Product: 6-(tert-Butyl)pyridin-3-amine The title of the patent was Cyclometalated arylpyridine and arylbenzimidazolylidene metal complexes as electroluminescent materials for organic light-emitting devices. And the patent contained the following:

Cyclometalated iridium complexes [(Q1-Q2)3Ir] (1), [(Q1-Q2)2(Q3-Q4)Ir] (2) and [(Q1-Q2)2IrL] (3; for 1-3: Q1, Q3 = substituted pyridinyl-κN, quinolinyl-κN, isoquinolinyl-κN, benzimidazolylidene-κC2; Q2, Q4 = substituted aryl-κC2; L = acetylacetonato, dipivaloylmethanato), useful as triplet-emitting dopants for light-emitting layers of organic electroluminescent devices (OLEDs), featuring better solubility in organic solvents and enhanced stability, were prepared by conventional cyclometalation, ligand substitution and derivatization reactions and tested for performance and electrooptical characteristics by manufacturing test OLEDs according to standard protocols. The homoleptic complexes 1 were prepared by cyclometalation of the corresponding ligands Q1-Q2H with [Ir(acac)3], typically as fac-isomers. The heteroleptic tris-cyclometalated complexes 2 were prepared via cationic intermediates [(Q1-Q2)2Ir(HOMe)2][OTf] (4), which were results of halogen abstraction and methanolysis of iridium dimers [(Q1-Q2)4Ir2(μ-Cl)2] (5), by cyclometalation of the ligands Q3-Q4H with 4. The complexes of the type 3 were prepared by complexation of dimers 5 or methanol complexes 4 with the β-diketones HL. The ligands in the some of the complexes 1 or 2 were modified by bromination, borylation and coupling reaction sequence; the bromides [(Q1-Q2-Br)3Ir] (6) were arylated via Suzuki coupling with arylboronates or converted into aromatic amines [(Q1-Q2-NR2)3Ir] (R = aryl, or NR2 = substituted 9-carbazolyl) by Buchwald amination reaction with amines HNR2 or carbazoles. The bromides 6 were also used as comonomers in Suzuki polymerization of arene and carbazole dibromides with arylenediboronates, giving electroluminescent polyarylene-polycarbazoles containing up to 10% of [(Q1-Q2)3Ir] structural fragments. In an example, reaction of 10 mmol of Na[(acac)2IrCl2] with 40 mmol of the proligand, 2-(1,2,3,4-tetrahydro-1,4-ethano-6-naphthyl)pyridine (H-LB1) in the presence of 3-10 g of propylene glycol as solvent at reflux for 100 h gave the reaction mixture, which was diluted with 50 mL of EtOH and 50 mL of 2 N HCl, the product was filtered off, and purified by EtOAc extraction to give the invented complex [(LB1)3Ir] (1a) with 49% yield. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Recommanded Product: 6-(tert-Butyl)pyridin-3-amine

The Article related to iridium cyclometalated arylpyridine arylquinoline arylisoquinoline arylbenzimidazole complex preparation electroluminescence, electroluminescent material iridium cyclometalated complex preparation luminescence oled manufacturing, bromination borylation suzuki buchwald coupling derivatization iridium cyclometalated complex and other aspects.Recommanded Product: 6-(tert-Butyl)pyridin-3-amine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem